Vir Biotechnology (VIR) Other Non-Current Liabilities (2018 - 2026)

Vir Biotechnology's Other Non-Current Liabilities history runs 9 years deep, the most recent figure standing at $33.2 million for Q1 2026.

• In Q1 2026, Other Non-Current Liabilities rose 40.48% year-over-year to $33.2 million; the TTM figure through Mar 2026 stood at $33.2 million (up 40.48% YoY), while the FY2025 annual figure was $21.6 million, down 10.28% from the prior year.
• Other Non-Current Liabilities came in at $33.2 million for Q1 2026 at Vir Biotechnology, up from $21.6 million in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $34.2 million in Q3 2025 to a low of $7.2 million in Q3 2022.
• A 5-year average of $23.7 million and a median of $24.9 million in 2023 frame the typical range for Other Non-Current Liabilities.
• Across the five-year window, Other Non-Current Liabilities surged 638.52% in 2022 and plunged 56.41% in 2023, its largest moves.
• Vir Biotechnology's Other Non-Current Liabilities stood at $24.9 million in 2022, then plunged by 36.7% to $15.8 million in 2023, then jumped by 52.37% to $24.0 million in 2024, then slipped by 10.28% to $21.6 million in 2025, then jumped by 53.91% to $33.2 million in 2026.
• According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $33.2 million, $21.6 million, and $34.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison